After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ZYME falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Zymeworks BC Inc is $2.00B. A total of 0.68 million shares were traded on the day, compared to an average of 1.13M shares.
In the most recent transaction, Galbraith Kenneth sold 47,528 shares of ZYME for 27.02 per share on Dec 22 ’25. After the transaction, the Chair & CEO now owns 133,275 company shares. In a previous transaction on Dec 22 ’25, Galbraith, Kenneth bought 47,528 shares at 27.23 per share.
Among the insiders who bought shares, Derek John Michael Miller acquired of 118,000 shares on Nov 24 ’25 at a per-share price of $23.82. In another insider transaction, Neil Gallagher bought 105,000 shares at $23.82 per share on Nov 21 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ZYME has a high of $28.49 and a low of $9.03.
As of this writing, ZYME has an earnings estimate of -$0.32 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of $0.24 per share and a lower estimate of -$0.72. The company reported an EPS of -$0.31 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $4.23, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.87.
